Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Perceptions of Pregnancy and Lactation from the Pregnancy and Lactation Autoimmune Network Registry.

Mills BS, Dao KH, Tecson KM, Beil EF, Tate R, Cush JJ.

J Rheumatol. 2019 Apr 1. pii: jrheum.181067. doi: 10.3899/jrheum.181067. [Epub ahead of print]

PMID:
30936282
2.

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years.

Lachowiez C, Cook RJ, Hayes-Lattin B, Maziarz RT, Borate U, Traer E, Leonard J, Newell L, Dao KH, Meyers G.

Hematol Oncol Stem Cell Ther. 2019 Jun;12(2):105-109. doi: 10.1016/j.hemonc.2019.01.002. Epub 2019 Mar 2.

3.

Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options.

Strauß R, Rose T, Flint SM, Klotsche J, Häupl T, Peck-Radosavljevic M, Yoshida T, Kyogoku C, Flechsig A, Becker AM, Dao KH, Radbruch A, Burmester GR, Lyons PA, Davis LS, Hiepe F, Grützkau A, Biesen R.

J Mol Med (Berl). 2017 Jul;95(7):753-765. doi: 10.1007/s00109-017-1515-7. Epub 2017 Mar 29.

PMID:
28357476
4.

Polycythemia Vera Management and Challenges in the Community Health Setting.

Gerds AT, Dao KH.

Oncology. 2017;92(4):179-189. doi: 10.1159/000454953. Epub 2017 Jan 18. Review.

5.

Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women.

Wiedmeier JE, Kato C, Zhang Z, Lee H, Dunlap J, Nutt E, Rattray R, McKay S, Eide C, Press R, Mori M, Druker B, Dao KH.

Exp Hematol. 2016 Sep;44(9):857-865.e5. doi: 10.1016/j.exphem.2016.05.009. Epub 2016 May 26.

6.

Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia.

Khanna V, Pierce ST, Dao KH, Tognon CE, Hunt DE, Junio B, Tyner JW, Druker BJ.

Cureus. 2015 Dec 17;7(12):e414. doi: 10.7759/cureus.414.

7.

A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.

Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW.

Leuk Lymphoma. 2016 Oct;57(10):2441-4. doi: 10.3109/10428194.2016.1138295. Epub 2016 Feb 8. No abstract available.

8.

Age-related mutations and chronic myelomonocytic leukemia.

Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, O'Hare T, Deininger MW.

Leukemia. 2016 Apr;30(4):906-13. doi: 10.1038/leu.2015.337. Epub 2015 Dec 9.

9.

What's different about atypical CML and chronic neutrophilic leukemia?

Dao KH, Tyner JW.

Hematology Am Soc Hematol Educ Program. 2015;2015:264-71. doi: 10.1182/asheducation-2015.1.264. Review. Erratum in: Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):717.

10.

Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism.

Garbati MR, Welgan CA, Landefeld SH, Newell LF, Agarwal A, Dunlap JB, Chourasia TK, Lee H, Elferich J, Traer E, Rattray R, Cascio MJ, Press RD, Bagby GC, Tyner JW, Druker BJ, Dao KH.

Am J Hematol. 2016 Feb;91(2):211-9. doi: 10.1002/ajh.24245.

11.

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW.

Leuk Res Rep. 2014 Aug 1;3(2):67-9. doi: 10.1016/j.lrr.2014.07.002. eCollection 2014.

12.

SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature.

Becker AM, Dao KH, Han BK, Kornu R, Lakhanpal S, Mobley AB, Li QZ, Lian Y, Wu T, Reimold AM, Olsen NJ, Karp DR, Chowdhury FZ, Farrar JD, Satterthwaite AB, Mohan C, Lipsky PE, Wakeland EK, Davis LS.

PLoS One. 2013 Jun 24;8(6):e67003. doi: 10.1371/journal.pone.0067003. Print 2013.

13.

The PI3K/Akt1 pathway enhances steady-state levels of FANCL.

Dao KH, Rotelli MD, Brown BR, Yates JE, Rantala J, Tognon C, Tyner JW, Druker BJ, Bagby GC.

Mol Biol Cell. 2013 Aug;24(16):2582-92. doi: 10.1091/mbc.E13-03-0144. Epub 2013 Jun 19.

14.

Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies.

Dao KH, Tyner JW.

Clin Cancer Res. 2013 Mar 15;19(6):1309-11. doi: 10.1158/1078-0432.CCR-12-3934. Epub 2013 Feb 4.

15.

A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.

Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, Jamieson CH.

Cell Stem Cell. 2013 Mar 7;12(3):316-28. doi: 10.1016/j.stem.2012.12.011. Epub 2013 Jan 17.

16.

ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.

Jiang Q, Crews LA, Barrett CL, Chun HJ, Court AC, Isquith JM, Zipeto MA, Goff DJ, Minden M, Sadarangani A, Rusert JM, Dao KH, Morris SR, Goldstein LS, Marra MA, Frazer KA, Jamieson CH.

Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1041-6. doi: 10.1073/pnas.1213021110. Epub 2012 Dec 28.

17.

Refining drug safety in rheumatology.

Cush JJ, Dao KH.

Rheum Dis Clin North Am. 2012 Nov;38(4):xi-xiv. doi: 10.1016/j.rdc.2012.10.001.

PMID:
23137585
18.

Malignancy risks with biologic therapies.

Cush JJ, Dao KH.

Rheum Dis Clin North Am. 2012 Nov;38(4):761-70. doi: 10.1016/j.rdc.2012.09.006. Review.

PMID:
23137581
19.

Nonserious infections: should there be cause for serious concerns?

Dao KH, Herbert M, Habal N, Cush JJ.

Rheum Dis Clin North Am. 2012 Nov;38(4):707-25. doi: 10.1016/j.rdc.2012.08.016. Review.

PMID:
23137578
20.

FANCL ubiquitinates β-catenin and enhances its nuclear function.

Dao KH, Rotelli MD, Petersen CL, Kaech S, Nelson WD, Yates JE, Hanlon Newell AE, Olson SB, Druker BJ, Bagby GC.

Blood. 2012 Jul 12;120(2):323-34. doi: 10.1182/blood-2011-11-388355. Epub 2012 May 31.

21.

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.

Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW.

Blood. 2010 Oct 28;116(17):3278-85. doi: 10.1182/blood-2008-10-183665. Epub 2010 Jun 2.

22.

Rac1 and Cdc42 are regulators of HRasV12-transformation and angiogenic factors in human fibroblasts.

Appledorn DM, Dao KH, O'Reilly S, Maher VM, McCormick JJ.

BMC Cancer. 2010 Jan 12;10:13. doi: 10.1186/1471-2407-10-13.

23.

Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.

Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, Heald AE.

J Rheumatol. 2010 Apr;37(4):692-703. doi: 10.3899/jrheum.090817. Epub 2009 Dec 23.

PMID:
20032102
24.

Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.

Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, Jones C, Zehnder JL, Keating A, Negrin RS, Weissman IL, Jamieson CH.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3925-9. doi: 10.1073/pnas.0900189106. Epub 2009 Feb 23.

25.

Increased prevalence of activated CD70+CD4+ T cells in the periphery of patients with systemic lupus erythematosus.

Han BK, White AM, Dao KH, Karp DR, Wakeland EK, Davis LS.

Lupus. 2005;14(8):598-606.

PMID:
16175931

Supplemental Content

Support Center